Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medicaid Expansion: Glass Half Full for Biopharma

This article was originally published in RPM Report

Executive Summary

Most health reform watchers have been tracking state votes on Medicaid expansion as a sort of scorecard on whether Obama Administration is winning or losing in health care reform. Push back from the states is making news now, but for biopharma sponsors, even a glass half full is a positive—and the long-term outlook is even brighter.

You may also be interested in...

Drug Spending Expected To Rise By $200 Bil. In 2022 Compared To Pre-ACA Levels

Implementation of the Affordable Care Act in 2014 will help significantly increase growth for pharma. The increase won’t be as big as it might have been, thanks to the Supreme Court ruling allowing states to opt out of Medicaid expansion, but it should still be a significant acceleration.

Medicaid Expansion: Can Texas Be Turned?

Visits from HHS Secretary Sebelius raise the question of whether Texas could change its mind and expand Medicaid eligibility under the ACA.

Managing ACA Expectations

Express Scripts CEO says prescription drug utilization will be flat in the first year of Medicaid expansion and insurance exchanges. With millions of Americans expected to get health coverage in 2014, can that projection be true?

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts